Literature DB >> 16849352

Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy.

R Idilman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16849352      PMCID： PMC1856256     

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  7 in total

1.  Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

Authors:  G Rossi; A Pelizzari; M Motta; M Puoti
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

2.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

3.  Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy.

Authors:  Ramazan Idilman
Journal:  J Antimicrob Chemother       Date:  2005-04-22       Impact factor: 5.790

4.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy.

Authors:  J H Hoofnagle; G M Dusheiko; D F Schafer; E A Jones; K C Micetich; R C Young; J Costa
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

Review 5.  Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.

Authors:  George V Papatheodoridis; Evangelini Dimou; Vasilios Papadimitropoulos
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

6.  Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.

Authors:  Oren Shibolet; Yaron Ilan; Shmuel Gillis; Ayala Hubert; Daniel Shouval; Rifaat Safadi
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

7.  Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.

Authors:  R Idilman; M Arat; E Soydan; M Törüner; I Soykan; H Akbulut; O Arslan; M Ozcan; A R Türkyilmaz; M Bozdayi; S Karayalçin; D H Van Thiel; A Ozden; M Beksaç; H Akan
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728
  7 in total
  5 in total

1.  Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.

Authors:  Yasunori Fujimoto; Naoya Hashimoto; Manabu Kinoshita; Yuko Miyazaki; Satoshi Tanaka; Takayuki Yakushijin; Tetsuo Takehara; Naoki Kagawa; Toshiki Yoshimine
Journal:  Int J Clin Oncol       Date:  2011-08-03       Impact factor: 3.402

2.  Reactivation of hepatitis B: pathogenesis and clinical implications.

Authors:  Anthony Post; Shweta Nagendra
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

3.  Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience.

Authors:  Orhan Onder Eren; Mehmet Artac; Melih Cem Boruban; Ozlem Yavas; Ugur Arslan; Metin Basaranoglu
Journal:  Med Oncol       Date:  2008-11-20       Impact factor: 3.064

4.  Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.

Authors:  Yihu Zheng; Shengchu Zhang; Hooi Min Tan Grahn; Chao Ye; Zheng Gong; Qiyu Zhang
Journal:  Hepat Mon       Date:  2013-04-01       Impact factor: 0.660

5.  Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

Authors:  Pınar Ataca Atilla; Merih Yalçıner; Erden Atilla; Ramazan İdilman; Meral Beksaç
Journal:  Turk J Haematol       Date:  2019-08-01       Impact factor: 1.831
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.